Archive for the ‘plos one’ Category
PLOS ONE has issued a fascinating expression of concern about data collection in a paper it published late last year on the possible spread of deadly viruses among Indonesian orangutans. The case has been brought to the attention of the Indonesian government, but more on that in a moment.
The article, published last July by an international group of primate scientists led by Chairul Nidom, a virologist at Indonesia’s Airlangga University, sounded an alarm about “wild” orangutans in Borneo: Blood tests of 353 “healthy” animals showed antibodies for viruses akin to Ebola. What’s more, the filoviruses viruses to which the antibodies responded, as New Scientist and other outlets reported when the original paper came out, included strains not previously seen outside Africa (as well as Marburg, another deadly infection).
A team of Swiss microbiologists has retracted their 2012 paper in PLoS One on the genetics of the TB mycobacterium after learning that the fusion protein they thought they’d used in their study was in fact a different molecule.
Here’s the retraction notice for the article, “A β-lactamase based reporter system for ESX dependent protein translocation in mycobacteria,” which has been cited once, according to Thomson Scientific’s Web of Knowledge: Read the rest of this entry »
A new study in Clinical Chemistry paints an alarming picture of how often scientists deposit data that they’re supposed to — but perhaps not surprisingly, papers whose authors did submit such data scored higher on a quality scale than those whose authors didn’t deposit their data.
Ken Witwer, a pathobiologist at Hopkins, was concerned that a lot of studies involving microarray-based microRNA (miRNA) weren’t complying with Minimum Information About a Microarray Experiment (MIAME) standards supposedly required by journals. So he looked at 127 such papers published between July 2011 and April 2012 in journals including PLOS ONE, the Journal of Biological Chemistry, Blood, and Clinical Chemistry, assigning each one a quality score and checking whether the authors had followed guidelines.
One is a casualty of our old friend, Jesús Lemus, the Spanish veterinary scientist accused of fabricating his data.
The article, titled “The PHA-Skin Test Reflects Acquired T-Cell Mediated Immunocompetence in Birds,” was published in September 2008 and cited 61 times, according to Google Scholar.
PLOS ONE has retracted an article it published earlier this year by a group from Australia who failed to receive adequate ethics approval for their study.
The paper, “Late Complications of Clinical Clostridium Histolyticum Collagenase Use in Dupuytren’s Disease,” came from Warren M. Rozen, Yasith Edirisinghe and John Crock (sorry, irony machine not working today). Dupuytren’s causes thickening of the fascia in the hands and often requires surgery. In 2011 the FDA approved a treatment for the ailment that involves injections of an enzyme — Clostridium Histolyticum Collagenase, or CHC — into the affected area.
The Aussie article looked at the effects of CHC injections in 12 patients over one year, finding that two of the patients suffered Read the rest of this entry »
October, apparently, is “studies of retractions month.” First there was a groundbreaking study in PNAS, then an NBER working paper, and yesterday PLoS Medicine alerted us to a paper their sister journal, PLoS ONE, published last week, “A Comprehensive Survey of Retracted Articles from the Scholarly Literature.”
The study, by Michael L. Grieneisen and Minghua Zhang, is comprehensive indeed, reaching further back into the literature than others we’ve seen, and also including more disciplines: Read the rest of this entry »
It’s pretty impressive to publish two peer-reviewed papers on complicated vaccination models while you’re still in high school. So it’s not surprising that Nathan Georgette, who grew up outside of Jacksonville, Florida, earned a prestigious fellowship from the Davidson Institute for Talent Development.
But perhaps even more impressive is realizing you’ve made a fundamental error in one of those studies, and retracting it while you’re still a college senior at Harvard. Read the rest of this entry »